To include your compound in the COVID-19 Resource Center, submit it here.

Erbitux cetuximab IMC-C225: Phase III

IMCL and partner Bristol-Myers Squibb Co. (BMY, Princeton, N.J.) are planning two Phase

Read the full 135 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE